A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
暂无分享,去创建一个
Harbani K. Malik-Chaudhry | A. Boudreau | N. Trinklein | Karen Chang | M. Cuturi | R. Buelow | U. Schellenberger | Katherine E. Harris | S. Iyer | A. Balasubramani | Laura M. Davison | P. Sankaran | K. Lorentsen | N. S. Allen | Brian C. Avanzino | Sharon Hartstein | Udaya S. Rangaswamy | Kaitlyn Loughlin | Harish Medlari Basappa | Ghenima Ahmil | Dennis M Ho
[1] F. Janku,et al. Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors , 2020 .
[2] H. Hirte,et al. 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1) , 2020 .
[3] S. Gettinger,et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). , 2020, Cancer discovery.
[4] J. Fisher,et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.
[5] J. Safrit,et al. The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques , 2020, PLoS pathogens.
[6] D. Neri,et al. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. , 2019, New biotechnology.
[7] E. L. Potter,et al. IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion , 2019, Clinical Cancer Research.
[8] Michael J. Osborn,et al. Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies , 2019, Front. Immunol..
[9] Brian D. Weitzner,et al. De novo design of potent and selective mimics of IL-2 and IL-15 , 2019, Nature.
[10] J. Desjarlais,et al. Abstract 5565: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure , 2018, Clinical Research (Excluding Clinical Trials).
[11] T. Nayak,et al. 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding , 2018, Oncotarget.
[12] Wei Wu,et al. Prospects of IL-2 in Cancer Immunotherapy , 2018, BioMed research international.
[13] Michael J. Osborn,et al. Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies , 2018, Front. Immunol..
[14] C. Klein,et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines , 2017, Oncoimmunology.
[15] B. Brannetti,et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2 , 2016, Science Translational Medicine.
[16] M. Addepalli,et al. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.
[17] O. Boyman,et al. Interleukin-2: Biology, Design and Application. , 2015, Trends in immunology.
[18] T. Anchordoquy,et al. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. , 2014, Drug discovery today.
[19] L. Radvanyi,et al. The IL-2 cytokine family in cancer immunotherapy. , 2014, Cytokine & growth factor reviews.
[20] S. Rosenberg. IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.
[21] R. Lufkin,et al. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program , 2014, Journal of Immunotherapy for Cancer.
[22] P. Hwu,et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. , 2014, The Journal of clinical investigation.
[23] Claudia C. Preston,et al. The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer , 2013, PloS one.
[24] J. Wolchok,et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma , 2013, The Journal of experimental medicine.
[25] H. Wong,et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma. , 2013, Cancer research.
[26] J. Sims,et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. , 2012, Cytokine.
[27] W. Klapper,et al. Targeting Interleukin-2 to the Neovasculature Potentiates Rituximab‘s Activity Against Mantle Cell Lymphoma in Mice , 2012 .
[28] Vijay S. Pande,et al. Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.
[29] J. Sprent,et al. The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.
[30] F. Carrat,et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.
[31] J. Ritz,et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.
[32] F. Marincola,et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.
[33] Saileta Prabhu,et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.
[34] Michael W. Sneddon,et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response , 2010, Molecular systems biology.
[35] F. D. De Braud,et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. , 2010, European journal of cancer.
[36] G. Pantaleo,et al. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells , 2010, Proceedings of the National Academy of Sciences.
[37] W. Klapper,et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. , 2009, Blood.
[38] Anne S De Groot,et al. Immunogenicity of protein therapeutics. , 2007, Trends in immunology.
[39] T. Waldmann. IL-15 in the life and death of lymphocytes: Implications for cancer therapy and vaccine design , 2007 .
[40] K. Rezvani,et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.
[41] T. Waldmann. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.
[42] A. Rudensky,et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.
[43] K. Christopher Garcia,et al. The Structure of Interleukin-2 Complexed with Its Alpha Receptor , 2005, Science.
[44] P. Parren,et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. , 2000, Cellular immunology.
[45] M. Doyle,et al. Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4 , 2000, The Journal of Immunology.
[46] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] S. Steinberg,et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.
[48] Camellia W. Adams,et al. An efficient route to human bispecific IgG , 1998, Nature Biotechnology.
[49] M. Madanat,et al. Intrachain disulfide bond in the core hinge region of human IgG4 , 1997, Protein science : a publication of the Protein Society.
[50] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.
[51] T. Loughran,et al. Establishment of an IL‐2 independent, human T‐cell line possessing only the p70 IL‐2 receptor , 1991, International journal of cancer.
[52] S. Morrison,et al. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region , 1991, The Journal of experimental medicine.
[53] S. Rosenberg,et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.
[54] V. Velcheti,et al. PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX, IN PATIENTS WITH ADVANCED SOLID TUMORS , 2018 .
[55] D. Pardoll,et al. Therapeutic administration of IL‐15 superagonist complex ALT‐803 leads to long‐term survival and durable antitumor immune response in a murine glioblastoma model , 2016, International journal of cancer.
[56] T. Waldmann,et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] M. Atkins,et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.